JP2016094425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016094425A5 JP2016094425A5 JP2015229868A JP2015229868A JP2016094425A5 JP 2016094425 A5 JP2016094425 A5 JP 2016094425A5 JP 2015229868 A JP2015229868 A JP 2015229868A JP 2015229868 A JP2015229868 A JP 2015229868A JP 2016094425 A5 JP2016094425 A5 JP 2016094425A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle
- group
- lipid
- distearoyl
- glycero
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 17
- 150000002632 lipids Chemical class 0.000 claims 11
- -1 acyl-peptides Natural products 0.000 claims 6
- 229910021645 metal ion Inorganic materials 0.000 claims 5
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229920001281 polyalkylene Polymers 0.000 claims 3
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims 1
- 229960005063 gadodiamide Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 claims 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15245909P | 2009-02-13 | 2009-02-13 | |
| US61/152,459 | 2009-02-13 | ||
| US16298909P | 2009-03-24 | 2009-03-24 | |
| US61/162,989 | 2009-03-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550316A Division JP5847588B2 (ja) | 2009-02-13 | 2010-02-16 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016094425A JP2016094425A (ja) | 2016-05-26 |
| JP2016094425A5 true JP2016094425A5 (enExample) | 2016-07-07 |
| JP6072205B2 JP6072205B2 (ja) | 2017-02-01 |
Family
ID=42562321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550316A Active JP5847588B2 (ja) | 2009-02-13 | 2010-02-16 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
| JP2015229868A Active JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550316A Active JP5847588B2 (ja) | 2009-02-13 | 2010-02-16 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20120087857A1 (enExample) |
| EP (1) | EP2398503B1 (enExample) |
| JP (2) | JP5847588B2 (enExample) |
| CN (2) | CN102341126A (enExample) |
| WO (1) | WO2010094043A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2833926A4 (en) * | 2012-04-05 | 2015-11-25 | Univ Florida | NEUROPHILIC NANOPARTICLES |
| GB2549861A (en) * | 2014-11-03 | 2017-11-01 | Albert Einstein College Medicine Inc | Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof |
| GB201509934D0 (en) | 2015-06-08 | 2015-07-22 | King S College London | Nanoparticles |
| CN107708672A (zh) * | 2015-06-15 | 2018-02-16 | 华盛顿大学 | 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法 |
| CN107412790B (zh) * | 2017-09-08 | 2019-02-22 | 丽水市中心医院 | 一种核磁共振纳米材料的制备方法 |
| US12226496B2 (en) | 2018-04-30 | 2025-02-18 | Bar-Ilan University | Polymeric core-shell particles |
| WO2020154623A1 (en) * | 2019-01-24 | 2020-07-30 | Alzeca Biosciences, LLC | Functionalized liposomes for imaging misfolded proteins |
| US11116854B2 (en) * | 2020-01-29 | 2021-09-14 | Texas Children's Hospital | Targeted contrast agents for MRI of amyloid deposition |
| CN113730614B (zh) * | 2021-09-09 | 2022-02-22 | 南京市第一医院 | 一种镥标记的纳米载体及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833948A (en) * | 1995-06-15 | 1998-11-10 | Bracco Research S.A. | Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant |
| EP1105162A1 (en) * | 1998-08-10 | 2001-06-13 | Bracco Research S.A. | Combination of a positive mri contrast agent with a negative mri contrast agent |
| US20030082103A1 (en) * | 2000-10-11 | 2003-05-01 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| US7514098B2 (en) * | 2001-05-30 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| US7459145B2 (en) * | 2002-10-25 | 2008-12-02 | Georgia Tech Research Corporation | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
| EP1648299A4 (en) * | 2003-07-09 | 2008-10-22 | California Pacific Med Center | REMOTE DETERMINATION OF THE DELIVERY OF SUBSTANCES IN CELLS |
| ES2531751T3 (es) | 2003-12-22 | 2015-03-18 | Bracco Suisse Sa | Montaje de microvesícula rellena de gas con componente activo para imagenología de contraste |
| US20050265922A1 (en) * | 2004-04-20 | 2005-12-01 | Emory University | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof |
| US20090238767A1 (en) * | 2004-12-17 | 2009-09-24 | Koninklijke Philips Electronics, N.V. | Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy |
| US8753673B2 (en) * | 2006-05-23 | 2014-06-17 | Taiwan Liposome Co. Ltd. | Liposome composition for delivery of a therapeutic agent to eyes |
| CA2680206C (en) * | 2007-03-05 | 2015-07-07 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
| KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
| WO2009110939A2 (en) * | 2007-12-10 | 2009-09-11 | Massachusetts Institute Of Technology | Drug delivery system for pharmaceuticals and radiation |
-
2010
- 2010-02-16 WO PCT/US2010/024324 patent/WO2010094043A2/en not_active Ceased
- 2010-02-16 CN CN2010800105605A patent/CN102341126A/zh active Pending
- 2010-02-16 CN CN201610996986.1A patent/CN106362171A/zh active Pending
- 2010-02-16 EP EP10741884.0A patent/EP2398503B1/en active Active
- 2010-02-16 JP JP2011550316A patent/JP5847588B2/ja active Active
-
2011
- 2011-08-11 US US13/208,100 patent/US20120087857A1/en not_active Abandoned
-
2015
- 2015-11-25 JP JP2015229868A patent/JP6072205B2/ja active Active
-
2016
- 2016-12-05 US US15/369,661 patent/US11207430B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016094425A5 (enExample) | ||
| Wang et al. | Diagnostic imaging and therapeutic application of nanoparticles targeting the liver | |
| Elbialy et al. | Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery | |
| CN102149371B (zh) | 螯合两亲聚合物 | |
| US20170348440A1 (en) | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | |
| CN102114000B (zh) | 一种载药的共输送脂质纳米递药系统 | |
| JP2012518012A5 (enExample) | ||
| US9844656B2 (en) | Localization of agents at a target site with a composition and an energy source | |
| Liu et al. | Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent | |
| JP6072205B2 (ja) | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 | |
| Le et al. | Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy | |
| JP2007515471A5 (enExample) | ||
| US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| JP2017052790A (ja) | ｓＰＬＡ２加水分解性リポソームを含む医薬組成物 | |
| JP2015502946A5 (enExample) | ||
| JP2018504450A (ja) | 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 | |
| Karpuz et al. | Lipid‐based drug delivery systems and their role in infection and inflammation imaging | |
| KR20150034517A (ko) | 소수성 활성 성분 및 폴리펩티드의 복합체를 포함하는 리포좀, 및 그의 용도 | |
| CN103619802B (zh) | 脂质模拟物化合物及其用途 | |
| Seo et al. | Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes | |
| JP7318876B2 (ja) | エステル結合で薬物が固定されたリガンドを含有する超音波造影剤を活用した超音波誘導薬物送達体 | |
| WO2013116645A1 (en) | Self-assembling molecules that accumulate in acidic tumor microenvironments | |
| US10842746B1 (en) | Bi-directionally crosslinked liposomes and method of making same | |
| Accardo et al. | Diolein based nanostructures as targeted theranostics | |
| Kaur et al. | Multifunctional liposome-based nanobiosystems |